Select Language
Siglec-3
Siglec-3 Overview
| English Name | Myeloid cell surface antigen CD33 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 37 | Target Synonym | Myeloid Cell Surface Antigen CD33，CD33 Molecule Transcript，CD33 Antigen，Siglec-3，P67，FLJ00391，Sialic acid-binding Ig-like lectin 3，CD33，CD33 Molecule，CD33 Antigen (Gp67)，SIGLEC3，Gp67，Sialic Acid Binding Ig-Like Lectin 3 |
| Highest Development Stage | Approved | ||
| English Name | Myeloid cell surface antigen CD33 |
| Target Synonym | Myeloid Cell Surface Antigen CD33，CD33 Molecule Transcript，CD33 Antigen，Siglec-3，P67，FLJ00391，Sialic acid-binding Ig-like lectin 3，CD33，CD33 Molecule，CD33 Antigen (Gp67)，SIGLEC3，Gp67，Sialic Acid Binding Ig-Like Lectin 3 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 37 |
| Highest Development Stage | Approved |
Siglec-3 Product List
- Product Category
Protein (17)Beads (1)
- Product Status
Launched (18)
- Species
Human (15)Cynomolgus (1)Mouse (1)Rat (1)
- Tag
His Tag (9)Fc Tag (4)His Tag & Avi Tag (2)- (1)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)
- Conjugate
Unconjugated (8)Biotin-labeled (3)FITC Labeled (2)- (1)PE Labeled (2)AF647 Labeled (1)APC Labeled (1)
Add to Cart
Total: 18
- 1
- 2
Siglec-3 Background
Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Iglike lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, one Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.
Siglec-3 Synonyms
CD33,SIGLEC3,gp67
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BI-836858 | BI-836858 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CART-33 (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225 (Actinium Pharmaceuticals) | 225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 | Phase 2 Clinical | Pdl Biopharma Inc | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| VBP-301 | VBP301; VBP-301 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute | Details |
| VBP-101 | VBP101; VBP-101 | Phase 2 Clinical | Vor Biopharma Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech) | BAH244; BAH-244 | Phase 2 Clinical | Essen Biotech | Leukemia, Myeloid, Acute | Details |
| VCAR-33 (Vor Biopharma) | VCAR-33; VCAR33 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CD33 CAR T Cells(Beijing Boren Hospital) | Phase 2 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia; Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| Vixtimotamab | T-564; AMV-564 | Phase 1 Clinical | Amphivena Therapeutics Inc | Solid tumours; Myelodysplastic Syndromes | Details |
| AL-003 | AL-003 | Phase 1 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
| PRGN-3006 | PRGN-3006; PRGN-3006 UltraCAR-T | Phase 1 Clinical | Precigen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| ORM-6151 | ORM-6151; BMS-986497 | Phase 1 Clinical | Orum Therapeutics Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| JNJ-89853413 | JNJ-89853413 | Phase 1 Clinical | Janssen Research & Development Llc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| GTB-3650 | GTB-3650; GTB-360; OXS-3350; OXS-C3550 | Phase 1 Clinical | Masonic Cancer Center, University Of Minnesota | Bone Marrow Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| JNJ-67571244 | JNJ-67571244; JNJ-67371244; JNJ-1244 | Phase 1 Clinical | Johnson & Johnson | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CD33-NKE | CD33-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Leukemia, Myeloid, Acute | Details |
| Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| CD33 CAR-NK cell therapy (Hangzhou Qihan) | Phase 1 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| Eluvixtamab | MT-114; AMG-330 | Phase 1 Clinical | Amgen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| BL-M11D1 | BL-M11D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| CD33 CAR-T Therapy (Shanghai YaKe/Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| anti-CD33 CAR T cells therapy（iCell Gene Therapeutics） | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225/Venetoclax | Phase 1 Clinical | Actinium Pharmaceuticals Inc | Leukemia, Promyelocytic, Acute | Details | |
| DXC-007 | DXC-007 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Lintuzumab-gelonin conjugate | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin | CMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicin | Approved | Ucb Sa, Pfizer Inc | Mylotarg | Japan | Leukemia, Myeloid, Acute | Pfizer Inc | 2008-01-18 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Product Reviews
K***n2023-05-06
0People LikeWhile transducing primary cells, I was running into a staining issue with biotinylated-rCD33. A colleague of mine had used rCD33 labelled with PE before and had success with a similar experiment. I decided to order from Acrobio Systems due to the recommendations and high praise from several colleagues. Upon staining, I saw great fluorescence, increased events caught, and higher transduction efficiencies. I will definitely be using this product again!- E***g2023-01-18 4People LikeWe purchased this reagent for use in detecting CD33 CAR expression and it worked as advertised. The PE signal gave great separation by flow cytometry and allowed for the clear detection of CAR expression on the surface of our cells._x000D_ _x000D_ The product page states that the CD33 PE reagent is incompatible with streptavidin-biotin detection systems. When we tried to co-stain with another biotinylated reagent, subsequent application of streptavidin-APC resulted in high non-specific APC staining. This could be avoided by staining with CD33 PE after all other staining steps have been completed.
- S***s2023-01-12 0People LikeWe purchased this antibody to use for flow cytometry on a client study, who specifically requested Acro antibodies! They are reliable and have continued to be one of our top providers of antibodies. We typically use multiple fluorescent antibodies with various protein targets and fluorophores at once for flow cytometry panels in human and mouse tissues, and Acro antibodies have always given us a great readout.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland